Malignant melanoma is 1 of the most aggressive types of human cancer. Its ability to metastasize, in combination with resistance to conventional anticancer chemotherapy, makes melanoma extremely difficult to cure and consequently, the median survival of metastatic melanoma patients is 8.5 months. Molecular mechanisms underlying melanoma progression are not completely understood, and good markers associated with specific stage(s) of tumor progression are yet to be determined. Elevated expression of the oncogene C-MYC was reported in melanoma, although a controversy remains as to what stage(s) this event occurs. We discovered that high amounts of C-MYC are maintained at the protein level in the majority of metastatic melanoma samples and melanoma cell lines. The overall hypothesis of our proposal is that viability of malignant melanoma depends on high levels of C-MYC. We demonstrated that high C-MYC levels and protein stability in several melanoma cell lines could not be fully accounted for by activation of MAPK-ERK pathway, and that inhibition of factors involved in proteosomal degradation of C-MYC is likely to participate in upregulation of C-MYC levels and protein stability in these cells. Expression analysis identified that among proteins promoting C-MYC proteolitic degradation, B56a subunit of PP2A phospahtase complex was underexpressed in all tested melanoma cell lines compared to normal melanocytes. Additionally, inhibition of PP2A-B56a subunit in melanoma cells caused upregulation of c-MYC levels. To identify MYC-target genes rate-limiting for melanoma cell viability, we stably inhibited C-MYC in several human melanoma cell lines by lentivirus-based shRNA. Depletion of C-MYC resulted in apoptosis and/or inhibition of proliferation accompanied by decreased amounts of intracellular deoxyribonucleoside triphopshates (dNTPs) and downregulation of several rate-limiting enzymes involved in dNTP metabolism. Importantly, apoptotic/cytostatic effects caused by C-MYC depletion were partially alleviated by supplementing cell media with precursors of nucleotide biosynthesis. We therefore propose to i) determine whether elevated C-MYC protein levels are associated with a specific stage of melanoma progression and ii) functionally characterize the role of PP2A-B56a in C-MYC-dependent melanocytic transformation and in C-MYC-mediated maintenance of viability of melanoma cells. iii) functionally characterize involvement of the identified enzymes in MYC-mediated control of the nucleotide metabolism and iv)identify rate-limiting steps of nucleotide metabolism affected in MYC-depleted cells using methods of biochemical analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA120244-05
Application #
8010153
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Ault, Grace S
Project Start
2008-05-12
Project End
2011-12-26
Budget Start
2010-12-01
Budget End
2011-12-26
Support Year
5
Fiscal Year
2011
Total Cost
$320,646
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Bianchi-Smiraglia, Anna; Nikiforov, Mikhail A (2016) Slowing down the Grand Touring Prototype speed of cancer cells. Mol Cell Oncol 3:
Bianchi-Smiraglia, A; Bagati, A; Fink, E E et al. (2016) Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools. Oncogene :
Bianchi-Smiraglia, A; Wawrzyniak, J A; Bagati, A et al. (2015) Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity. Cell Death Differ 22:1858-64
Zucker, Shoshanna N; Fink, Emily E; Bagati, Archis et al. (2014) Nrf2 amplifies oxidative stress via induction of Klf9. Mol Cell 53:916-28
Burkhart, Catherine A; Haber, Michelle; Norris, Murray D et al. (2013) Cell-based methods for the identification of MYC-inhibitory small molecules. Methods Mol Biol 1012:255-64
Wawrzyniak, Joseph A; Bianchi-Smiraglia, Anna; Bshara, Wiam et al. (2013) A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion. Cell Rep 5:493-507
Mannava, Sudha; Moparthy, Kalyana C; Wheeler, Linda J et al. (2013) Depletion of deoxyribonucleotide pools is an endogenous source of DNA damage in cells undergoing oncogene-induced senescence. Am J Pathol 182:142-51
Liu, Xinyue; Hu, Qiang; Liu, Song et al. (2013) Serum Antibody Repertoire Profiling Using In Silico Antigen Screen. PLoS One 8:e67181
Mannava, S; Omilian, A R; Wawrzyniak, J A et al. (2012) PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells. Oncogene 31:1484-92
Mannava, Sudha; Moparthy, Kalyana C; Wheeler, Linda J et al. (2012) Ribonucleotide reductase and thymidylate synthase or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion. Aging (Albany NY) 4:917-22

Showing the most recent 10 out of 21 publications